Cannabix Technologies Develops Beta 3.0 Marijuana Breathalyzer and Provides Update
July 31 2017 - 8:00AM
Cannabix Technologies Inc. (CSE:BLO) (OTC PINK:BLOZF) (the “Company
or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for
law enforcement and the workplace, is pleased to announce that it
has developed a “Beta 3.0” (Cannabix Marijuana Breathalyzer) device
based on its FAIMS- (field asymmetric waveform ion mobility
spectrometry) technology with major advances in the design and
commercial capabilities of the device. The Beta 3.0 will include a
conventional rechargeable battery, improved ion flow, the latest
pulse driver chips to improve resolution and sensitivity. The new
design includes improvements that will allow for dynamic testing
and for easier configurability that will be needed for more
demanding test/user environments.
The Beta 3.0 device will also include a specialized flow-through
heat exchanger technology that stabilizes breath temperature in
cold as well as humid temperature settings and allows for breath
testing in all temperature conditions. The new device includes
improved dielectric barrier discharge ionization source and
high-voltage square wave generator which has been given superior
voltage shielding. The Beta 3.0 device incorporates real time
breath analysis for concentrations of O2, CO2, humidity,
temperature and flow-rate which will allow for key metrics for
real-time detection of delta-9-tetrahydrocannabinol (“THC”) in
human breath.
Testing update and Establishment of British Columbia Testing
Laboratory
Cannabix has been developing its FAIMS based Cannabix Marijuana
Breathalyzer for the detection of THC through exhaled breath and
continues testing its devices in British Columbia and Florida for
sensitivity and consistency of results for Evidential Breath
testing purposes.
Recent testing with the Cannabix Marijuana Breathalyzer Beta 2.0
prototype device with human subjects after smoking THC cigarettes
demonstrated the successful identification of THC in relation to
the subject’s background matrix in real-time. (THC being the
psychoactive component of marijuana). In addition to THC, several
metabolites were identified in the breath of the human subjects
including 11-hydroxy-delta-9-tetrahydrocannabinol and
delta-9-carboxy-tetrahydrocannabinol, the results were confirmed by
mass spectrometry after the inhalation of cannabis.
The Company has substantially increased its testing capabilities
with investment in a state-of-the art lab space in Vancouver, B.C.,
purchase of Thermo Scientific mass spectrometer and related
equipment. Cannabix has also added to its technical team with the
addition of Dr. David Hasman who is an expert in the field of
toxicology and forensic science as well the operation of mass
spectrometer based testing devices.
Furthermore, the Company is in discussions to collaborate, using
the Cannabix Marijuana Breathalyzer, with a significant U.S. based
institution with large user group and enhanced testing
environment.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer
development for law enforcement and the workplace. Cannabix has
established breath testing technologies in the pursuit of bringing
durable, portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects use days or even weeks earlier.
The devices will also be useful for other practical applications
such as testing employees in the workplace where intoxication by
THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (v) the ability of the Company to develop and
market its future product; and (vi) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies Inc.
Phone: (604) 551-7831
Fax: 604-676-2767
info@cannabixtechnologies.com
www.cannabixtechnologies.com
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Sep 2023 to Sep 2024